Cargando…

CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells

CIGB-300 is a clinical-grade anti-Protein Kinase CK2 peptide, binding both its substrate’s phospho-acceptor site and the CK2α catalytic subunit. The cyclic p15 inhibitory domain of CIGB-300 was initially selected in a phage display library screen for its ability to bind the CK2 phospho-acceptor doma...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramón, Ailyn C., Basukala, Om, Massimi, Paola, Thomas, Miranda, Perera, Yasser, Banks, Lawrence., Perea, Silvio E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414295/
https://www.ncbi.nlm.nih.gov/pubmed/36016303
http://dx.doi.org/10.3390/v14081681
_version_ 1784775953642160128
author Ramón, Ailyn C.
Basukala, Om
Massimi, Paola
Thomas, Miranda
Perera, Yasser
Banks, Lawrence.
Perea, Silvio E.
author_facet Ramón, Ailyn C.
Basukala, Om
Massimi, Paola
Thomas, Miranda
Perera, Yasser
Banks, Lawrence.
Perea, Silvio E.
author_sort Ramón, Ailyn C.
collection PubMed
description CIGB-300 is a clinical-grade anti-Protein Kinase CK2 peptide, binding both its substrate’s phospho-acceptor site and the CK2α catalytic subunit. The cyclic p15 inhibitory domain of CIGB-300 was initially selected in a phage display library screen for its ability to bind the CK2 phospho-acceptor domain ofHPV-16 E7. However, the actual role of this targeting in CIGB-300 antitumoral mechanism remains unexplored. Here, we investigated the physical interaction of CIGB-300 with HPV-E7 and its impact on CK2-mediated phosphorylation. Hence, we studied the relevance of targeting E7 phosphorylation for the cytotoxic effect induced by CIGB-300. Finally, co-immunoprecipitation experiments followed by western blotting were performed to study the impact of the peptide on the E7–pRB interaction. Interestingly, we found a clear binding of CIGB-300 to the N terminal region of E7 proteins of the HPV-16 type. Accordingly, the in vivo physical interaction of the peptide with HPV-16 E7 reduced CK2-mediated phosphorylation of E7, as well as its binding to the tumor suppressor pRB. However, the targeting of E7 phosphorylation by CIGB-300 seemed to be dispensable for the induction of cell death in HPV-18 cervical cancer-derived C4-1 cells. These findings unveil novel molecular clues to the means by which CIGB-300 triggers cell death in cervical cancer cells.
format Online
Article
Text
id pubmed-9414295
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94142952022-08-27 CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells Ramón, Ailyn C. Basukala, Om Massimi, Paola Thomas, Miranda Perera, Yasser Banks, Lawrence. Perea, Silvio E. Viruses Article CIGB-300 is a clinical-grade anti-Protein Kinase CK2 peptide, binding both its substrate’s phospho-acceptor site and the CK2α catalytic subunit. The cyclic p15 inhibitory domain of CIGB-300 was initially selected in a phage display library screen for its ability to bind the CK2 phospho-acceptor domain ofHPV-16 E7. However, the actual role of this targeting in CIGB-300 antitumoral mechanism remains unexplored. Here, we investigated the physical interaction of CIGB-300 with HPV-E7 and its impact on CK2-mediated phosphorylation. Hence, we studied the relevance of targeting E7 phosphorylation for the cytotoxic effect induced by CIGB-300. Finally, co-immunoprecipitation experiments followed by western blotting were performed to study the impact of the peptide on the E7–pRB interaction. Interestingly, we found a clear binding of CIGB-300 to the N terminal region of E7 proteins of the HPV-16 type. Accordingly, the in vivo physical interaction of the peptide with HPV-16 E7 reduced CK2-mediated phosphorylation of E7, as well as its binding to the tumor suppressor pRB. However, the targeting of E7 phosphorylation by CIGB-300 seemed to be dispensable for the induction of cell death in HPV-18 cervical cancer-derived C4-1 cells. These findings unveil novel molecular clues to the means by which CIGB-300 triggers cell death in cervical cancer cells. MDPI 2022-07-30 /pmc/articles/PMC9414295/ /pubmed/36016303 http://dx.doi.org/10.3390/v14081681 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ramón, Ailyn C.
Basukala, Om
Massimi, Paola
Thomas, Miranda
Perera, Yasser
Banks, Lawrence.
Perea, Silvio E.
CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
title CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
title_full CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
title_fullStr CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
title_full_unstemmed CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
title_short CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
title_sort cigb-300 peptide targets the ck2 phospho-acceptor domain on human papillomavirus e7 and disrupts the retinoblastoma (rb) complex in cervical cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414295/
https://www.ncbi.nlm.nih.gov/pubmed/36016303
http://dx.doi.org/10.3390/v14081681
work_keys_str_mv AT ramonailync cigb300peptidetargetstheck2phosphoacceptordomainonhumanpapillomaviruse7anddisruptstheretinoblastomarbcomplexincervicalcancercells
AT basukalaom cigb300peptidetargetstheck2phosphoacceptordomainonhumanpapillomaviruse7anddisruptstheretinoblastomarbcomplexincervicalcancercells
AT massimipaola cigb300peptidetargetstheck2phosphoacceptordomainonhumanpapillomaviruse7anddisruptstheretinoblastomarbcomplexincervicalcancercells
AT thomasmiranda cigb300peptidetargetstheck2phosphoacceptordomainonhumanpapillomaviruse7anddisruptstheretinoblastomarbcomplexincervicalcancercells
AT pererayasser cigb300peptidetargetstheck2phosphoacceptordomainonhumanpapillomaviruse7anddisruptstheretinoblastomarbcomplexincervicalcancercells
AT bankslawrence cigb300peptidetargetstheck2phosphoacceptordomainonhumanpapillomaviruse7anddisruptstheretinoblastomarbcomplexincervicalcancercells
AT pereasilvioe cigb300peptidetargetstheck2phosphoacceptordomainonhumanpapillomaviruse7anddisruptstheretinoblastomarbcomplexincervicalcancercells